TUntil now, his year, some of the largest pharmaceutical corporations in the world took about £ 2 billion in the proposed investments From Great Britain. One even threatened to keep new medicines for patients with NHS. Taken together, it is difficult not to come to the conclusion that the large farm is in the war with the UK.
Merk canceled The research center in the amount of 1 billion pounds, while Astrazeneca abandoned the vaccine laboratory of 450 million pounds and rethinks the expansion of another research unit. Bristol Myers Squibb (BMS) canceled 34 partnerships with NHS last year, and Eli Lilly, Sanofi and Novartis are believed to have stopped investments. BMS too threatening to play hardball With a new cure of schizophrenia, saying that he is “ready to make a difficult decision” to “leave” if the NHS does not pay the price that he wants to charge the price.
One high-ranking government official told The Financial Times that, apparently, the companies work together, saying that the speed of the industry’s threat machine gun “looks very coordinated”. They marked behavior “Empterial” and said that they “have never seen anything like this before.” (The head of the Association of the British Pharmaceutical Industry stated that such an accusation is “very serious” and “categorically incorrect.”) Three non -governmental organizations, including the one on which I work, asked for competition and markets to further study this.
One way to understand the actions of the industry is as a full -scale strike of capital, in which international capital refuses to invest in order to intimidate the government into concessions. In this case, the expenses of NHS drugs are the obvious point of dispute. In the industry, it has long been at the National Institute Health And Excellence Care (Nice), the body that allows NHS to judge the cost of drugs and, in fact, agrees on prices. And this is even less pleased with the voluntary scheme for the price, access and growth of branded drugs (VPAG), which allows the government to return some of their income when the prices paid by NHS are growing too quickly – program What the industry called “unstable.” In short, Big Pharma hates power that NHS should reduce its obscene prices. And he uses every opportunity to push this power.
The last opportunity appears in the form of Donald Trump. It is no coincidence that the screams of Big Pharma became hysterical during the recent state visit of the US President to the UK. Trump must see that he is dealing with prices for the accounting opinions in the United States, a country where the pharmaceutical industry really earns its money.
Traditionally, the United States contained little to hold back the prices of medicines. Biden began to resist the industry, forcing the company to negotiate prices. Trump's decision differs from the type, he believes that the problem is not that they do not have any specific corporations in a desperate need for regulation, but load foreigners. Until the end of the month, he was given pharmaceutical companies to begin to align global prices. No one knows what will happen next, although tariffs are up to 200% were proposedField
IN his tariff agreement with Trump Earlier this year, Starmer promised to “improve the overall environment for pharmaceutical companies.” Trump did not forget. In the “frosty” Meeting with Rachel Reeves Earlier this month, the US Ambassador Ambassador to London resolutely pushed the Chancellor to offer companies the best deal of drug prices.
Big Pharma uses any crisis as an opportunity to increase its already high profit. With the support of Trump, he is determined to promote his long -term goals.
This is simply not the case when Britain pays too little for his medicines. Last year, NHS England spent close to 20 billion pounds for medicines and devicesThe study field has repeatedly shown that branded Medicines are actually too expensiveAnd not too cheap, for the advantages that they offer patients, even with discounts and claws.
The truth is that Big Pharma is already one of the most profitable industries in the world. The disgust of the larger number of extended NHS budgets to please these fantastically rich global corporations will not help patients. Minister of Science Patrick Walland said this week that significant Raising prices was necessary To finish the dispute. UES is a stroke, the Minister of Health, still stood his ground, correctly stating that he had already made a generous proposal. Despite all of ours, the government should be firmly.
This is probably the case when Britain underestimates in medical research. But the transfer of empty checks by Big Pharma will not lead us to the best drugs. Instead, we must take this opportunity to put an end to the deterioration that these companies have over our healthcare and restructure how we make our medicines. It will cost money. But medicines in any case are from the condition.
We must work with countries throughout Europe in order to create, publicly controlled medical studies of the world class. Then, instead of transmitting this study to the pharmaceutical industry, we must develop another model that allows the exchange and licensing of research in such a way as to maintain international cooperation for the production of the best drugs for everyone.
After increasing the newsletter
At the same time, we need to increase production capacities. The state does not need to produce every medicine that we need, but we need more public capabilities, so we can never adhere to the ransom again.
Finally, we must work with countries in the world south to help increase their research and production capacities, violating large pharma -dominance at the international level, as well as at the national level.
A large pharma flourishes in dominance, bullying and exclusion. A NHS was built on precisely opposite principles. Let's take this opportunity to expand the values with which we use our medicines before we produce them.
